文献速递泌尿男性生殖肿瘤

高血清钠预测转移性肾细胞癌和尿路上皮癌的免疫治疗反应

High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma.
PubMed 文献 · Eur J Cancer · 2024-04-28

该研究对两项3期临床试验(IMvigor211用于转移性尿路上皮癌,IMmotion151用于转移性肾细胞癌)共1787例患者进行事后分析,评估基线血清电解质水平的预后和预测价值。发现基线血清钠和氯与预后呈线性相关,高基线血清钠(>140 mmol/L)患者客观缓解率最高,且血清钠作为免疫治疗疗效预测指标优于肿瘤PD-L1表达。

要点

  • 基线血清钠和氯与两项试验的预后呈线性相关,钾、镁、钙未见此关联。
  • IMmotion151中基线血清钠>140 mmol/L的mRCC患者完全缓解率为17.9%,而<135 mmol/L者为2.0%。
  • 血清钠作为免疫治疗疗效预测指标优于肿瘤PD-L1表达。

核心结论

  • 血清钠水平升高的患者从免疫治疗中获益最大,提示基线血清浓度可作为跨瘤种的有价值且成本效益好的预测生物标志物。

研究设计与样本

  • 对两项独立3期临床试验进行事后分析:IMvigor211(转移性尿路上皮癌,比较阿替利珠单抗与化疗)和IMmotion151(转移性肾细胞癌,比较阿替利珠单抗+贝伐珠单抗与舒尼替尼)。
  • 共分析1787例患者(IMvigor211 n=901;IMmotion151 n=886),评估基线钠、钾、氯、镁和钙水平的预后和预测价值。

主要发现

  • 两项试验中基线血清钠和氯与预后呈线性相关,钾、镁和钙未发现此关联。
  • 多变量分析中,钠的预后能力仅限于接受ICI的患者,与对照组相比。
  • 两项研究中,基线血清钠>140 mmol/L的患者亚组达到客观缓解的机会最高;IMmotion151中mRCC患者基线钠>140 mmol/L者完全缓解率为17.9%,而基线钠<135 mmol/L者为2.0%。
  • 血清钠作为免疫治疗疗效预测指标优于肿瘤PD-L1表达。

关键数值与推荐

  • 基线血清钠>140 mmol/L:IMmotion151中mRCC患者完全缓解率17.9%。
  • 基线血清钠<135 mmol/L:IMmotion151中mRCC患者完全缓解率2.0%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The development of reliable biomarkers for the prediction of immune checkpoint inhibition (ICI) response in patients with metastatic renal cell carcinoma (mRCC) and urothelial carcinoma (mUC) remains an unresolved challenge. Conventional ICI biomarkers typically focus on tumor-related factors such as PD-L1 expression. However, a comprehensive evaluation of the predictive value of serum electrolyte levels, a so far widely unexplored area, is still pending. METHODS: We conducted a post-hoc analysis of baseline sodium, potassium, chloride, magnesium and calcium levels in two independent phase 3 clinical trials: IMvigor211 for mUC comparing atezolizumab to chemotherapy, and IMmotion151 for mRCC comparing atezolizumab+bevacizumab to sunitinib. This analysis aimed to evaluate the prognostic and predictive value of these electrolyte levels in these clinical settings. A total of 1787 patients (IMvigor211 n = 901; IMmotion151 n = 886) were analyzed. RESULTS: We found a linear correlation of baseline serum sodium and chloride with prognosis across both trials, which was not found for potassium, magnesium and calcium. In multivariate analysis, the prognostic capacity of sodium was limited to patients receiving ICI as compared to the control group. Interestingly, in both studies, the chance of achieving an objective response was highest in the patient subgroup with high baseline serum sodium levels of > 140 mmol/L (IMmotion151: Complete response in 17.9% versus 2.0% in patients with mRCC with baseline sodium < 135 mmol/L). Serum sodium outperformed tumor PD-L1 expression as a predictor for immunotherapy efficacy. CONCLUSIONS: Patients exhibiting elevated serum sodium levels derive the greatest benefit from immunotherapy, suggesting that baseline serum concentration could serve as a valuable and cost-effective predictive biomarker for immunotherapy across entities.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Klümper N, Cox A, Eckstein M, et al. High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma. Eur J Cancer. 2024. PMID: 38703618. doi:10.1016/j.ejca.2024.114089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。